High-dose oxygen-ozone therapy

in cancer patients: efficacy, mechanisms and therapeutic potential

Abstract

This article provides a systematic review of the effects of high-dose ozone therapy as a complementary treatment in cancer patients. Ozone therapy has demonstrated the potential to improve tumor oxygenation, modulate immune responses, and reduce the toxicity associated with conventional cancer treatments. Through a systematic review of the literature, we examine in detail the studies evaluating its efficacy as an adjuvant, its impact on oxidative stress, and its modulation of the tumor microenvironment and patient quality of life. The findings highlight the potential of ozone therapy as a complementary approach capable of alleviating the adverse effects of traditional cancer treatments while simultaneously improving their efficacy. However, the limitations of current studies underscore the need for further research to establish optimal protocols and validate long-term benefits.

Keywords

Ozone therapy; Integrative oncology; Tumor microenvironment; Adjuvant cancer therapy

Introduction

In recent years, ozone therapy has gained attention as a promising complementary approach in oncology, mainly due to its unique ability to induce controlled oxidative stress that selectively targets cancer while leaving healthy tissues relatively unaffected. Tumor cells are metabolically distinct from normal cells, displaying rapid proliferation, reduced oxidative defenses, and a high dependence on glycolytic pathways, a phenomenon often described as the Warburg effect [1]. The Warburg effect highlights how tumor cells produce energy predominantly through glycolysis, even in the presence of oxygen, a process that results in a lower antioxidant capacity and makes them particularly vulnerable to oxidative therapies such as ozone.

Ozone (O₃) therapy involves the administration of ozone gas at controlled doses, which leads to the production of reactive oxygen species (ROS) in the body. ROS are highly reactive molecules that can penetrate cell membranes and cause oxidative damage to vital cellular components such as DNA, proteins, and lipids. This damage, in turn, can trigger apoptosis, or programmed cell death, in tumor cells, a characteristic that has been extensively studied in various types of cancer, including breast, lung, cervical, and colorectal cancer [2].

Historically, ozone has been recognized for its antibacterial, antiviral, and anti-inflammatory properties, and has been used in wound care and as a disinfectant for over a century. Its application in oncology, however, is more recent, with studies exploring its potential to improve tumor oxygenation, support immune function, and alleviate the adverse effects of chemotherapy and radiation therapy. Given its unique biological actions and minimal toxicity when used properly, ozone therapy has been proposed as an adjuvant treatment in integrative oncology. This review examines the current literature on high-dose ozone therapy, focusing on its biochemical mechanisms, clinical outcomes, and therapeutic potential in cancer treatment.

Mechanisms of action

Ozone and reactive oxygen species (ROS)

When ozone is administered, it rapidly decomposes to form various ROS, including hydrogen peroxide, superoxide ions, and hydroxyl radicals. These ROS have a profound impact on tumor cells due to their high reactivity with cellular structures. ROS can oxidize cell membrane lipids, destroy proteins, and cause DNA strand breaks, resulting in cellular damage that tumor cells struggle to repair. The inability of tumor cells to mitigate oxidative damage is attributed to their low levels of antioxidant enzymes, such as catalase, superoxide dismutase (SOD), and glutathione peroxidase [3].

The presence of ROS in the cellular environment can lead to oxidative stress, a state in which an imbalance occurs between the production of ROS and the cell's ability to detoxify these reactive intermediates. In tumor cells, which already operate with a reduced capacity to handle oxidative stress, the introduction of ozone therapy exacerbates this stress, overwhelming their defense mechanisms and triggering cell death pathways [2].

Selective toxicity in tumor cells

The selective vulnerability of tumor cells to ozone-induced ROS lies in their reduced antioxidant capacity. Unlike normal cells, which possess a robust antioxidant defense system, tumor cells often lack sufficient levels of enzymes such as SOD and catalase, which neutralize ROS. This deficiency makes them more susceptible to the oxidative effects of ozone, whereas healthy cells can generally withstand low to moderate levels of oxidative stress [1].

Studies have shown that ozone exposure leads to a concentration-dependent increase in ROS in tumor cells, resulting in oxidative damage that triggers apoptosis. Apoptosis, or programmed cell death, is a controlled process that eliminates damaged cells without causing inflammation, a key advantage in the tumor microenvironment, where uncontrolled cell death can exacerbate disease progression.

Mitochondrial impact and apoptosis

One of the key mechanisms through which ozone induces cell death is mitochondrial destruction. Mitochondria are critical for energy production in cells, and their membranes are particularly sensitive to oxidative damage. When ROS levels increase, they can compromise mitochondrial membrane potential, leading to the release of pro-apoptotic factors such as cytochrome c. Once in the cytosol, cytochrome c activates caspase enzymes, which degrade cellular components and ultimately lead to apoptosis [4].

This mitochondrial effect of ozone is particularly effective against tumor cells, which depend on impaired mitochondrial function to sustain their rapid growth. By targeting and disrupting these energy-producing organelles, ozone therapy impairs tumor cell proliferation while sparing healthy cells, which can restore their mitochondrial function more efficiently.

Methodology

A systematic review was conducted using several scientific databases, including PubMed, ScienceDirect, and Google Scholar. Search terms included "Ozone Therapy and Cancer," "High-Dose Ozone Therapy," and "Ozone and Reactive Oxygen Species." Studies were selected based on their focus on the effects of ozone therapy in oncology, particularly those related to oxidative stress, immune modulation, tumor oxygenation, and quality of life outcomes. The review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to ensure transparency and methodological rigor [5].

Each study was assessed for quality and relevance using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) method. The studies included a variety of research designs, from in vitro and in vivo experiments to observational clinical studies and randomized controlled trials, providing a solid body of evidence on the efficacy and mechanisms of ozone therapy in cancer treatment.

Results

Effects on oxidative stress and cell death

Ozone-induced apoptosis

High-dose ozone therapy induces apoptosis in a variety of tumor cell types, including breast, lung, colorectal, and cervical cancers. This apoptotic process is initiated by elevated levels of ROS, which cause oxidative damage to cell membranes, proteins, and nucleic acids. Studies reveal that ROS production leads to lipid peroxidation and mitochondrial dysfunction, which activate both intrinsic and extrinsic apoptotic pathways. Mitochondrial membrane disruption, in particular, releases cytochrome, triggering the caspase cascade that dismantles the cell [2].

In studies of breast cancer cell lines, ozone exposure resulted in dose-dependent cell death, with higher ozone concentrations generating more robust ROS production and apoptosis. These findings are consistent with similar observations in lung cancer and melanoma cells, where ozone-induced apoptosis has been shown to limit tumor cell proliferation without affecting surrounding healthy tissue [4].

Synergy with chemotherapy

The synergy of ozone with chemotherapy drugs such as cisplatin and 5-fluorouracil represents a significant advantage, as it improves drug uptake into tumor cells and amplifies its cytotoxic effects. This synergy is particularly valuable in patients who experience severe side effects due to high doses of chemotherapy. By integrating ozone therapy, physicians may be able to reduce the dosage of chemotherapy drugs, mitigating adverse effects and maintaining therapeutic efficacy. In clinical trials of cervical cancer, patients treated with combined ozone and radiotherapy showed significant reductions in tumor volume and less gastrointestinal toxicity than those treated with radiotherapy alone [6].

In vitro studies on colorectal cancer cells have shown that ozone therapy enhances the effects of chemotherapy by disrupting tumor cell membranes and facilitating drug entry. This disruption weakens tumor cell defenses, allowing chemotherapeutic agents to reach higher intracellular concentrations and induce greater cytotoxicity [7].

Modulation of the tumor microenvironment and immunity

Oxygenation of the tumor

One of the major challenges in oncology is overcoming hypoxia in the tumor microenvironment, as low oxygen levels contribute to treatment resistance. Ozone therapy has demonstrated a significant ability to increase oxygenation in hypoxic tumors, thereby improving the efficacy of radiotherapy. In glioblastoma, an aggressive and highly hypoxic tumor type, increased oxygenation due to ozone therapy sensitizes cells to radiation by promoting the formation of ROS during radiotherapy, which amplifies DNA damage in tumor cells and reduces hypoxia-induced resistance mechanisms [8].

Ozone's ability to enhance oxygen diffusion is also valuable in poorly vascularized tumors, which benefit from improved blood flow and oxygen delivery. By reversing hypoxic conditions, ozone creates a more favorable environment for both chemotherapy and radiotherapy, improving their efficacy against otherwise resistant tumor cells [9].

Immune modulation

Ozone therapy has been shown to activate immune responses by increasing the production of ROS, which stimulates the activity of immune cells such as macrophages, dendritic cells, and natural killer (NK) cells. These immune responses are crucial for the identification and destruction of tumor cells. ROS from ozone therapy act as signaling molecules that increase the release of pro-inflammatory cytokines, such as TNF-α and IFN-γ, creating an immunoactivated environment favorable for anti-tumor responses [3].

Studies in immunocompromised cancer patients have shown that ozone therapy can reduce inflammatory markers and support immune recovery, which is beneficial for patients undergoing treatments that suppress immune function, such as chemotherapy. These immunomodulatory effects suggest that ozone therapy could complement existing cancer immunotherapies, improving their efficacy and potentially broadening their applicability [10].

Effects on quality of life and reduction of toxicity

Reduction of side effects

Ozone therapy has been associated with significant improvements in quality of life by reducing common side effects of cancer treatments, including fatigue, nausea, pain, and gastrointestinal problems. These symptoms are often exacerbated by chemotherapy and radiation therapy, contributing to decreased patient compliance and well-being. Clinical studies have shown that ozone therapy alleviates these symptoms, allowing patients to better tolerate and adhere to their treatment regimens [5].

Tolerability and safety

The safety profile of ozone therapy is favorable, with minimal adverse effects reported in clinical trials. Ozone selectively targets tumor cells while sparing healthy cells, making it a valuable adjuvant to conventional treatments. Patients undergoing ozone therapy experience fewer treatment interruptions, faster recovery, and improved physical resilience, which collectively contribute to improved oncology outcomes [11].

Discussion

Comparative analysis with conventional adjuvants

Ozone therapy offers unique advantages over traditional adjuvant therapies, such as hyperthermia and high-dose vitamin C, which are also used to support cancer treatment. While hyperthermia focuses on raising tumor temperature to sensitize tumor cells to radiation or chemotherapy, and high-dose vitamin C acts as an antioxidant with potential pro-oxidant effects in tumor cells, ozone therapy offers a dual benefit, both by ameliorating oxidative stress within tumors and by supporting immune modulation. This dual mechanism distinguishes ozone from other adjuvant treatments, as it not only directly targets tumor cells but also promotes an immune response that could further inhibit tumor progression [3].

Comparative studies also indicate that the safety profile of ozone therapy is superior to that of some conventional adjuvants. While therapies such as high-dose vitamin C can cause adverse effects such as nephrotoxicity in some patients, ozone therapy has been shown to be well tolerated with minimal side effects. Furthermore, the ability of ozone therapy to improve oxygenation in hypoxic tumors makes it particularly suitable for integration with radiotherapy, which relies on the presence of oxygen for the generation of ROS that damage the DNA of tumor cells [9].

Overall, ozone's selective cytotoxicity, immunomodulatory properties, and safety profile make it a promising candidate for broader application in integrative oncology. However, limitations in dosage standardization and the lack of large-scale randomized trials have limited its clinical adoption. Further research comparing ozone therapy with established adjuvants is needed to determine its relative efficacy and optimal use scenarios.

Mechanistic hypotheses and clinical implications

The mechanisms underlying ozone therapy are still under investigation, but current hypotheses suggest that its main antitumor effects result from a combination of oxidative stress induction and immune modulation. A prevailing hypothesis is that ozone-generated ROS selectively target tumor cells due to their impaired antioxidant defenses. Furthermore, ozone appears to exert an immunostimulatory effect by activating various immune cells and inducing pro-inflammatory cytokines, which may create an immunoactivated tumor environment that further compromises tumor growth and resistance [8].

These effects are particularly significant in tumors known for their immune-evasive properties, such as melanoma and glioblastoma. Ozone's potential to enhance immune responses aligns well with immunotherapy strategies, suggesting it could be an effective complement to immune checkpoint inhibitors. Some studies suggest that ozone's modulation of the immune microenvironment could enhance the effects of immunotherapies, making tumors more susceptible to immune attack. However, the clinical applications of ozone therapy in combination with immunotherapy require further studies to determine optimal protocols and dosages.

Limitations and areas for future research

Despite promising preclinical and clinical results, the current body of literature on ozone therapy is limited by several factors. First, the lack of standardized dosing protocols makes it difficult to compare results across studies. Different studies use different ozone concentrations and administration routes (e.g., intravenous, intraperitoneal, and topical), which can significantly influence the results. Establishing a consensus on standardized dosages and administration techniques will be essential to advance ozone therapy in clinical oncology [12].

Furthermore, most available studies are small-scale or observational, with few randomized controlled trials to rigorously validate the efficacy and safety of ozone. The heterogeneity of study populations and cancer types also limits the generalizability of the findings. Larger, well-designed randomized trials with diverse patient populations are needed to confirm the therapeutic potential of ozone therapy in different cancer types and to explore its long-term effects on survival and recurrence rates.

Finally, exploring ozone therapy in combination with emerging treatments such as CAR-T cell therapy, immune checkpoint inhibitors, and targeted therapies could unlock new synergistic effects. Future research should focus on these combined approaches to assess whether ozone can improve outcomes when combined with cutting-edge cancer treatments.

Conclusion

High-dose ozone therapy represents a promising complementary approach in oncology, particularly for its potential to reduce the toxicity of conventional therapies, improve tumor oxygenation, and support immune function. This dual action of direct tumor cytotoxicity through oxidative stress and indirect modulation of the immune response makes ozone an attractive candidate for integrated cancer therapy.

Existing literature indicates that ozone therapy can improve treatment tolerance and patient quality of life, crucial factors for maintaining adherence to rigorous cancer treatments. By alleviating the side effects of chemotherapy and radiotherapy, such as fatigue, nausea, and gastrointestinal disturbances, ozone therapy could improve patient resilience, potentially resulting in improved outcomes. Furthermore, ozone's ability to improve oxygenation in hypoxic tumors makes it a valuable adjuvant to radiotherapy, as well-oxygenated tumors respond more favorably to radiation.

Despite these encouraging results, further research is needed to overcome current limitations. The lack of standardized dosing protocols and the paucity of large-scale randomized clinical trials remain significant obstacles to clinical deployment. To fully validate ozone therapy as a reliable component of integrative oncology, future studies will need to focus on developing standardized protocols, conducting multicenter studies, and analyzing long-term patient outcomes, including survival and recurrence rates.

In conclusion, although preliminary evidence supports ozone therapy as a beneficial adjunct to conventional cancer treatments, well-designed clinical trials are essential to confirm its safety, efficacy, and applicability to various cancer types. If future research confirms these initial findings, ozone therapy has the potential to become a valuable tool for comprehensive, patient-centered cancer care, offering improved outcomes and a better quality of life for patients undergoing cancer treatment.

The author declares no conflict of interest regarding the publication of this article. The research presented was conducted independently, and no financial, personal, or professional affiliations have influenced the findings or conclusions reported.

Copyright and permissions

All rights to the content, figures, tables, and other materials in this article are reserved by the author. Any reproduction, distribution, or use of this material for publication, including translation, or for commercial purposes requires the author's prior written permission.

References

Hack CT, Buck T, Bagnjuk K, Eubler K, and Kunz L et al. (2019). A role for H2O2 and TRPM2 in the induction of cell death: studies in KGN cells. Antioxidants. 8(11):518.

Stein BE, Clamann HP, and Goldberg SJ. (1980) Superior colliculus: control of eye movements in newborn kittens. Science. 210(4465):78-80.

Simonetti V. (2017). Evidence-based complementary and alternative medicine.

Clavo B. (2018). Evidence-based complementary and alternative medicine.

Sanchez JC, Garcia BN, Ruano A, Blanco M and Sanchez BC et al. (2021) Impact of the COVID19 pandemic on the hospitalization burden of oncology patients: results of a quasi-experimental study. J clin oncol.

Sun T, Wang T, Li X, Wang H, and Mao Y. (2023) Tumor-infiltrating lymphocytes provide novel insights into survival of HER2-low-positive early breast cancer: a large-cohort retrospective study. Front Oncol. 13:1148228.

Clavo B, Perez J, Lopez L, Suarez G and Lloret M et al. (2004) Ozone therapy for oxygenation of cancers: a pilot study. Evid Based Complement Alternat Med. 1(1):93–98.

Rojas A, Meherem S, Young-Ho K, Washington MK, and Willis JE et al. (2008) Aberrant TSP1 methylation suppresses TGF-beta1 activation in colorectal cancer. Int J Cancer. 123(1):14–21.

Enzelsberger H et al. (1987). Obstetrics and Gynecology.

Jiao ZH, Wang JD, and Wang XJ. (2018) MicroRNA-16 suppressed osteosarcoma invasion and migration by directly inhibiting RAB23. Eur Rev Med Pharmacol Sci. 22(9):2598–2605.

Byrd JC, Hillmen P, Ghia P, Kater AP, and Chanan-khan A et al. (2021) Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III study. J Clin Oncol. 39(31):3441–3452.

Menéndez, S., et al. (2008). Ozone: Science and Engineering.

Agarwal, B. (2019). Journal of Medical Sciences and Clinical Research.

Baeza-Noc J and Pinto-Bonilla, R. (2021). International Journal of Molecular Sciences.

Lahodny J. (2022). Journal of Ozone Therapy.

Luongo M et al. (2017). Cancer research.

Zhao-ra, L. (2010). Medical Innovation in China.

Rodriguez-Esparragón F, et al. (2019). Antioxidants

John K, Rosner I, Keilholz U, Gauler T, and Bental H et al. (2015). Baseline caspase activity predicts progression-free survival in head and neck cancer patients treated with temsirolimus. Eur J Cancer. 51(12):1596-602

Fakhreddine MH, Galvan E, Pawowski J, and Jones 3rd WE. (2017). Communicating effectively with older cancer patients. Int J Radiat Oncol Biol Phys. 98(4):741–742.

Ayman D. (2020). Comparison of immediate implant placement in infected and noninfected extraction sockets provides limited data to guide practice. J Evid Based Dent Pract. 20(2):101420.

Costa, T., et al. (2018). Acta Medica Portuguesa.

Leung J. (2016). Regarding Canal et al. Int J Radiat Oncol Biol Phys. 94(5):1223.

Anderson, E., et al. (2021). Journal of Contemporary Brachytherapy.